Exercise can delay cognitive decline in people with rare Alzheimer's disease, finds a new study.
Engaging in physical activity for at least 2.5 hours per week may delay cognitive decline in individuals who carry genetic markers that cause Alzheimer's disease, reports a new study. The findings of the study are published in the journal Alzheimer's & Dementia. According to the authors, these results support the benefit of physical activity on cognition and dementia progression, even in individuals with autosomal dominant Alzheimer's disease (ADAD), a rare genetically-driven form of the disease in which the development of dementia at a relatively young age is inevitable.
‘A physically active lifestyle may delay cognitive decline in individuals with genetic risk for rare Alzheimer's disease.’
The authors say their results, "show a significant relationship between physical activity, cognition, functional status, and Alzheimer's disease pathology even in individuals with genetically-driven ADAD. The officially recommended physical activity duration of 150 minutes per week was associated with significantly better cognition and less Alzheimer's disease pathology in ADAD. From a public health perspective, this amount of physical activity was achieved by 70% of all ADAD individuals participating in the DIAN study. Therefore, a physically active lifestyle is achievable and may play an important role in delaying the development and progression of ADAD."
"The results of this study are encouraging, and not only for individuals with rare genetically-caused Alzheimer's disease," said Maria C. Carrillo, Ph.D., Chief Science Officer for the Alzheimer's Association. "If further research confirms this relationship between physical activity and later onset of dementia symptoms in ADAD, then we need to expand the scope of this work to see if it also is true in the millions of people with more common, late-onset Alzheimer's."
Christoph Laske, M.D. and his research team at the University Hospital of Tübingen, Germany analyzed data generated from 275 individuals (average age 38.4) who carry a genetic mutation for ADAD and are participating in the Dominantly Inherited Alzheimer's Network (DIAN), an international observational study of individuals and families with ADAD led by researchers at Washington University School of Medicine in St. Louis.
Researchers aimed to determine if at least 150 minutes of physical activity (walking, running, swimming, aerobics, etc.) per week the current recommendation by the World Health Organization and the American College of Sports Medicine - would produce cognitive benefits for the study participants. One hundred fifty-six (156) were classified as high physical activity individuals (>150 minutes physical activity/week); 68 as low physical activity individuals (<150 minutes physical activity/week). Exercise intensity was not measured, but the type and frequency were corroborated by a source such as a family member or a friend.
Advertisement
"A physically active lifestyle is achievable and may play an important role in delaying the development and progression of ADAD. Individuals at genetic risk for dementia should, therefore, be counseled to pursue a physically active lifestyle," the study authors conclude.
Advertisement
To more definitively generate scientific evidence on how lifestyle choices affect brain health, the Alzheimer's Association is currently leading a large two-year clinical trial called the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). The study is a two-year clinical trial to evaluate whether lifestyle interventions that simultaneously target many risk factors protect cognitive function in older adults who are at increased risk for cognitive decline. U.S. POINTER is the first such study to be conducted in a large group of Americans across the United States.
"Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer`s disease," by Dr. Stephan Muller, et al, was supported by The Dominantly Inherited Alzheimer's Network (DIAN, U19AG032438), U.S. National Institute on Aging, German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Japan Agency for Medical Research and Development, AMED, and Korea Health Industry Development Institute (KHIDI).
Source-Eurekalert